{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T22:49:02Z","timestamp":1648594142936},"reference-count":66,"publisher":"Elsevier","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008]]},"DOI":"10.1016\/s1571-5078(07)00220-6","type":"book-chapter","created":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T12:20:30Z","timestamp":1208953230000},"page":"229-240","source":"Crossref","is-referenced-by-count":0,"title":["Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids"],"prefix":"10.1016","author":[{"given":"Johannes W.J.","family":"Bijlsma","sequence":"first","affiliation":[]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Antonio P.","family":"da Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1571-5078(07)00220-6_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guide-lines for the management of rheumatoid arthritis: 2002 Update","volume":"46","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1677\/joe.0.1780347","article-title":"Mechanisms of steroid action and resistance in inflammation. Corticosteroid-insensitive asthma: molecular mechanisms","volume":"178","author":"Adcock","year":"2003","journal-title":"J. Endocrinol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0889-8529(05)70348-0","article-title":"Growth suppression by glucocorticoid therapy","volume":"25","author":"Allen","year":"1996","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/S1571-5078(07)00220-6_bib4","first-page":"78","article-title":"Molecular mechanisms of glucocorticoid effects","volume":"2","author":"Almawi","year":"2001","journal-title":"Mod. Asp. Immunobiol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib5","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 Update","volume":"44","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1096\/fj.03-0328com","article-title":"Membrane glucocorticoid receptors (mGCR) are expressed in normal peripheral blood mononuclear cells and upregulated following in vitro stimulation and in patients with rheumatoid arthritis","volume":"18","author":"Bartholome","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/S1571-5078(07)00220-6_bib7","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1210\/jc.86.12.5737","article-title":"GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone","volume":"86","author":"Bechtold","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/S1571-5078(07)00220-6_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.62.11.1033","article-title":"Glucocorticoids in the treatment of early and late RA","volume":"62","author":"Bijlsma","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.62.9.842","article-title":"The influence of corticosteroids and disease activity on total and HDL-cholesterol in patients with rheumatoid arthritis (RA)","volume":"62","author":"Boers","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S1571-5078(07)00220-6_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/03009740510017706","article-title":"The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis","volume":"34","author":"Buttgereit","year":"2005","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0039-128X(01)00171-4","article-title":"Rapid glucocorticoid effects on immune cells","volume":"67","author":"Buttgereit","year":"2002","journal-title":"Steroids"},{"key":"10.1016\/S1571-5078(07)00220-6_bib14","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","article-title":"Glucocorticoids in the treatment of rheumatic diseases. An update on mechanisms of action","volume":"50","author":"Buttgereit","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1749-6632.2000.tb05448.x","article-title":"Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications","volume":"917","author":"Chikanza","year":"2000","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/S1571-5078(07)00220-6_bib16","unstructured":"Criswell, L.A., Saag, K.G., Sems, K.M., Welch, V., Shea, B., Wells, G., Suarez-Almazor, M.E. 2000. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD001158, 2000."},{"key":"10.1016\/S1571-5078(07)00220-6_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.bjp.0703272","article-title":"Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism","volume":"130","author":"Croxtall","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib18","first-page":"282","article-title":"Hypothalamic\u2013pituitary\u2013adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids","volume":"26","author":"Cutolo","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.autrev.2005.04.019","article-title":"Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms","volume":"4","author":"Cutolo","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/S1571-5078(07)00220-6_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low-dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib21","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1073\/pnas.97.8.3919","article-title":"Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell","volume":"97","author":"De Bosscher","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1571-5078(07)00220-6_bib22","first-page":"1496","article-title":"Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis","volume":"28","author":"Dekkers","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib23","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/ard.54.5.379","article-title":"Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response","volume":"54","author":"Gaffney","year":"1995","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard.2003.008060","article-title":"Prevention of glucocorticoid induced osteoporosis. A consensus document of the Dutch Society for Rheumatology","volume":"63","author":"Geusens","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/S1571-5078(07)00220-6_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archinte.1994.00420010131015","article-title":"Glucocorticoids and the risk for initiation of hypoglycemic therapy","volume":"154","author":"Gurwitz","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/S1571-5078(07)00220-6_bib28","first-page":"277","article-title":"Hypothalamic\u2013pituitary\u2013adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation","volume":"26","author":"Gutierrez","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.58.11.713","article-title":"A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects","volume":"58","author":"Hansen","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/38.4.298","article-title":"Is there a defect in cortisol production in rheumatoid arthritis?","volume":"38","author":"Harbuz","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/S1571-5078(07)00220-6_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1677\/joe.0.1780055","article-title":"Hypothalamo\u2013pituitary\u2013adrenal axis dysregulation in patients with rheumatoid arthritis after the dexamethasone\/corticotrophin releasing factor test","volume":"178","author":"Harbuz","year":"2003","journal-title":"J. Endocrinol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0889-8529(05)70271-1","article-title":"Diabetes management in special situations","volume":"26","author":"Hirsch","year":"1997","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/S1571-5078(07)00220-6_bib33","doi-asserted-by":"crossref","unstructured":"Hoes, J.N., Jacobs, J.W.G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., Choy, E.H., Cutolo, M., Da Silva, J.A., Esselens, G.H., Guillevin, L., Hafstr\u00f6m, I., Kirwan, J.R., Rovensky, J., Russell, A.S., Saag, K.G., Svensson, B., Westhovens, R., Zeidler, H., Bijlsma, J.W. 2007. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 66, 1560\u20131567.","DOI":"10.1136\/ard.2007.072157"},{"key":"10.1016\/S1571-5078(07)00220-6_bib34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00007890-199102000-00020","article-title":"Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporin-treated renal transplant patients","volume":"51","author":"Hricik","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/S1571-5078(07)00220-6_bib35","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/art.21809","article-title":"Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo","volume":"54","author":"Jacobs","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib36","series-title":"Kelley's Textbook of Rheumatology","first-page":"859","article-title":"Glucocorticoid therapy","author":"Jacobs","year":"2005"},{"key":"10.1016\/S1571-5078(07)00220-6_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis: the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group","volume":"333","author":"Kirwan","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S1571-5078(07)00220-6_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","article-title":"COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention","volume":"46","author":"Landewe","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.fjc.0000245242.57088.5b","article-title":"Potent potentiating diuretic effects of prednisone in congestive heart failure","volume":"48","author":"Liu","year":"2006","journal-title":"J. Cardiovasc Pharmacol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrm1009","article-title":"Non-genomic actions of steroid hormones","volume":"4","author":"L\u00f6sel","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2004-12-4790","article-title":"Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn","volume":"106","author":"L\u00f6wenberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/S1571-5078(07)00220-6_bib42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1749-6632.1999.tb07622.x","article-title":"Perturbations of hypothalamic\u2013pituitary\u2013gonadal axis and adrenal androgen functions in rheumatoid arthritis: an odyssey of hormonal relationships to the disease","volume":"876","author":"Masi","year":"1999","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/S1571-5078(07)00220-6_bib44","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/MCB.15.3.1747","article-title":"Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes","volume":"15","author":"O\u2019Brien","year":"1995","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.10092","article-title":"Treating rheumatoid arthritis early: a window of opportunity?","volume":"46","author":"O\u2019Dell","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib46","first-page":"1632","article-title":"Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis","volume":"27","author":"Paulus","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/rheumatology\/keg425","article-title":"Serum cortisol reduction and abnormal prolactin and CD4+\/CD8+ T-cell response as a result of controlled exercise in patients with rheumatoid arthritis and systemic lupus erythematosus despite unaltered muscle energetics","volume":"43","author":"Pool","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/S1571-5078(07)00220-6_bib48","first-page":"57","article-title":"Exogenous corticosteroid effects on mood and cognition: case presentations","volume":"37","author":"Reckart","year":"1990","journal-title":"Int. J. Psychosom."},{"key":"10.1016\/S1571-5078(07)00220-6_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/S1571-5078(07)00220-6_bib50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/berh.2001.0157","article-title":"Corticosteroid osteoporosis","volume":"15","author":"Sambrook","year":"2001","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharm. Ther."},{"key":"10.1016\/S1571-5078(07)00220-6_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0300372101","article-title":"Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects","volume":"101","author":"Sch\u00e4cke","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1571-5078(07)00220-6_bib53","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2005.048272","article-title":"Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway","volume":"65","author":"Spies","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib54","first-page":"225","article-title":"Does stress influence the course of rheumatic diseases?","volume":"24","author":"Straub","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib55","first-page":"1219","article-title":"Further evidence for insufficient hypothalamic\u2013pituitary\u2013glandular axes in polymyalgia rheumatica","volume":"33","author":"Straub","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/art.20747","article-title":"How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis","volume":"52","author":"Straub","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/S1571-5078(07)00220-6_bib57","first-page":"1659","article-title":"Infusion of epinephrine decreases serum levels of cortisol and 17-hydroxyprogesterone in patients with rheumatoid arthritis","volume":"29","author":"Straub","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib58","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1210\/jc.83.6.2012","article-title":"Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence","volume":"83","author":"Straub","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/S1571-5078(07)00220-6_bib59","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucoccorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Ver. Infect. Dis."},{"key":"10.1016\/S1571-5078(07)00220-6_bib60","unstructured":"The Royal College of Physicians, The Bone and Tooth Society of Great Britain, and The National Osteoporosis Society. 2002. Glucocorticoid-induced osteoporosis. Guidelines for Prevention and Treatment. London, December 2002. (www.rcplondon.ac.uk\/pubs\/books\/glucocorticoid\/index. asp)."},{"key":"10.1016\/S1571-5078(07)00220-6_bib61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00002512-199915060-00004","article-title":"Corticosteroids and glaucoma risk","volume":"15","author":"Tripathi","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/S1571-5078(07)00220-6_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial","volume":"136","author":"Van Everdingen","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/S1571-5078(07)00220-6_bib63","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int."},{"key":"10.1016\/S1571-5078(07)00220-6_bib64","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/ki.1987.131","article-title":"Mechanisms of glucocorticoid-induced hypertension","volume":"31","author":"Whitworth","year":"1987","journal-title":"Kidney Int."},{"key":"10.1016\/S1571-5078(07)00220-6_bib66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1677\/joe.0.1780331","article-title":"Mechanisms of steroid action and resistance in inflammation. Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness","volume":"178","author":"Wikstr\u00f6m","year":"2003","journal-title":"J. Endocrinol."},{"key":"10.1016\/S1571-5078(07)00220-6_bib67","series-title":"Principles of Corticosteroid Therapy","first-page":"166","article-title":"Corticosteroids and the integument","author":"Wolverton","year":"2002"}],"container-title":["Handbook of Systemic Autoimmune Diseases","Endocrine Manifestations of Systemic Autoimmune Diseases"],"original-title":[],"deposited":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T15:58:14Z","timestamp":1546099094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1571507807002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":66,"URL":"https:\/\/doi.org\/10.1016\/s1571-5078(07)00220-6","relation":{},"ISSN":["1571-5078"],"issn-type":[{"value":"1571-5078","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}